|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006141,
umls-concept:C0006142,
umls-concept:C0010583,
umls-concept:C0015737,
umls-concept:C0021853,
umls-concept:C0087111,
umls-concept:C0178602,
umls-concept:C0205217,
umls-concept:C0205225,
umls-concept:C0220825,
umls-concept:C0439810,
umls-concept:C0543467,
umls-concept:C1522673,
umls-concept:C1709701,
umls-concept:C2607943,
umls-concept:C2926606
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2000-1-18
|
|
pubmed:abstractText |
In 1989, the National Surgical Adjuvant Breast and Bowel Project initiated the B-22 trial to determine whether intensifying or intensifying and increasing the total dose of cyclophosphamide in a doxorubicin-cyclophosphamide combination would benefit women with primary breast cancer and positive axillary nodes. B-25 was initiated to determine whether further intensifying and increasing the cyclophosphamide dose would yield more favorable results.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:AbramsonNN,
pubmed-author:AndersonSS,
pubmed-author:AtkinsJ NJN,
pubmed-author:BegovicMM,
pubmed-author:DavilaEE,
pubmed-author:DeCillisAA,
pubmed-author:DimitrovNN,
pubmed-author:FehrenbacherLL,
pubmed-author:FisherBB,
pubmed-author:HammJ TJT,
pubmed-author:HenryP HPH,
pubmed-author:KardinalC GCG,
pubmed-author:KellerA MAM,
pubmed-author:LanierK SKS,
pubmed-author:LaufmanLL,
pubmed-author:PierceH IHI,
pubmed-author:RomondE HEH,
pubmed-author:Tan-ChiuEE,
pubmed-author:TibaAA,
pubmed-author:WickerhamD LDL,
pubmed-author:WolmarkNN
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3374-88
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:10550131-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10550131-Breast Neoplasms,
pubmed-meshheading:10550131-Chemotherapy, Adjuvant,
pubmed-meshheading:10550131-Cyclophosphamide,
pubmed-meshheading:10550131-Disease-Free Survival,
pubmed-meshheading:10550131-Dose-Response Relationship, Drug,
pubmed-meshheading:10550131-Doxorubicin,
pubmed-meshheading:10550131-Female,
pubmed-meshheading:10550131-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:10550131-Humans,
pubmed-meshheading:10550131-Life Tables,
pubmed-meshheading:10550131-Mastectomy, Radical,
pubmed-meshheading:10550131-Middle Aged,
pubmed-meshheading:10550131-Treatment Failure
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25.
|
|
pubmed:affiliation |
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212-5234, USA. bernard.fisher@nsabp.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Multicenter Study
|
